viewSareum Holdings PLC

Sareum Holdings to showcase potential of new cancer drug at leading industry conference

The poster presentation is based on pre-clinical work on its TYK2/JAK1 inhibitor, SAR-20351

Sareum Holdings PLC -

Sareum Holdings PLC (LON:SAR) said it will make a poster presentation next month to a leading cancer conference based around pre-clinical work on its TYK2/JAK1 inhibitor.

It will describe how the company’s drug candidate SAR-20351 “significantly reduces” tumour growth in disease models for pancreatic, colon, skin and kidney cancers, plus B-cell lymphoma.

Positive results were gleaned when the prospective treatment was used on its own and in combination with chemotherapy.

The early-stage study suggests SAR-20351 promotes an anti-tumour effect by activating the local immune system to attack cancer cells.

Chief executive Tim Mitchell said: “Our data suggest that our TYK2/JAK1 inhibitors also offer the potential advantage of oral delivery; this contrasts with currently marketed cancer immunotherapies, which can only be dosed by injection.”

The poster will be presented at the American Association for Cancer Research National Cancer Institute European Organisation for Research and Treatment of Cancer International Conference in Boston on October 29.

Quick facts: Sareum Holdings PLC

Price: 0.805 GBX

Market: AIM
Market Cap: £26.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...


Sareum Holdings says Phase I clinical trials for CHK1 could potentially...

Tim Mitchell, chief executive officer at cancer drug discovery company Sareum Holdings (LON:SAR), talks to Proactive Investors about the progress achieved by all of its programmes in the half year ended December 31, 2015. He says Phase I clinical trials for CHK1, its most advanced...

on 02/24/2016

2 min read